Coronavirus Update - 09th November 2020

We would like to reassure our customers that as England enters its second national lockdown period, we remain open for business and at full capacity as we have done since the start of this pandemic and fully comply with all government guidance on minimising the risks of COVID-19.

As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

Our work and case studies

Challenge: Rapid development of a scalable route towards an analogue of a new drug substance, with definition of an optimal salt form for formulation


US Biotech client developing combined Small Molecule / Biologic immunotherapy treatments


ARCINOVA developed two process route options and selected one on the basis of scalability and process economy. The API free base was generated and a rapid salt screening protocol undertaken. A solubility study was undertaken which showed optimal solubilisation at a set pH. The client was delighted and has filed provisional IP. The drug substance analogue shows superior solubility to the prime API.


API Development Case Study BEL